NEW YORK–(BUSINESS WIRE)–NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has now determined to immediately suspend trading in the common stock of Blonder Tongue Laboratories, Inc. (the “Company”) ─ ticker symbol BDR ─ from the Exchange. This follows the Exchange’s December 10, 2021 announcement initiating delisting proceedings.
The Company had requested a review of the NYSE American delisting determination before a Committee of the Board of Directors of the Exchange. On June 24, 2022, the Company provided formal notification of its intention to withdraw its request for such review.
Accordingly, the NYSE American will now suspend trading in the common stock and will file a delisting application with the Securities and Exchange Commission.
Chief Financial Officer
Chief Executive Officer